Free Widgets | Feedback 
Live Share Markets -

Updated:27 Feb 2017 03:31:00 PM(IST)

Investor Tool

My Stockwatch 

RELIANCE 1238.90 [ +4.75% ]TCS 2489.85 [ +0.32% ]

-80.09 -0.28%

-42.80 -0.48%

1.67 0.01%

22.10 0.16%

Bse Corporate Announcements Back
Cipla updates on Stempeutics Research, a JV with Cipla Group
Cipla announced that Stempeutics Research, a group company of Manipal Education and Medical Group and a Joint Venture with Cipla Group has been granted a US process patent for its novel stem-cell based drug Stempeucel® by the United States Patent and Trademarks Office (USPTO).

Stempeucel® will initially be used for the treatment of Critical Limb Ischemia (CLI) and is a breakthrough treatment option which directly addresses the root cause of the disease, unlike other drugs which typically treat the symptoms and not the disease itself.

Market on Mobile

Site Map  •  Mobile  •  Companies  •  Learning Centre  •  Insurance •  About  •  Contact us  •  Disclaimer